Pathfinder Wealth Consulting Inc. Invests $2.91 Million in Eli Lilly and Company $LLY

Key Points

• Pathfinder Wealth Consulting initiated a new position in Eli Lilly, buying 2,705 shares worth about $2.91 million. The stake now represents roughly 1.8% of the firm’s portfolio, making LLY its 14th-largest holding.
• Recent analyst sentiment remains bullish, with Goldman Sachs reiterating a Buy rating and lifting its price target to $1,283, while Jefferies raised its target to $1,330. Broader analyst coverage still shows a Moderate Buy consensus and an average target of about $1,220.
• Eli Lilly reported strong quarterly results, posting $8.55 EPS and $19.80 billion in revenue, both above expectations. Revenue jumped 55.5% year over year, and the company also announced a quarterly dividend of $1.73 per share.

Pathfinder Wealth Consulting Inc. bought a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 2,705 shares of the company's stock, valued at approximately $2,907,000. Eli Lilly and Company comprises approximately 1.8% of Pathfinder Wealth Consulting Inc.'s investment portfolio, making the stock its 14th biggest holding.

A number of other hedge funds have also recently bought and sold shares of the stock. Cidel Asset Management Inc. increased its position in shares of Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock valued at $20,392,000 after purchasing an additional 5,591 shares during the period. Spire Wealth Management lifted its position in Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after purchasing an additional 592 shares during the period. Coldstream Capital Management Inc. lifted its position in Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock worth $32,365,000 after purchasing an additional 8,659 shares during the period. Farther Finance Advisors LLC boosted its stake in Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company's stock worth $33,471,000 after buying an additional 7,338 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in Eli Lilly and Company by 3.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company's stock valued at $126,022,000 after buying an additional 5,595 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LLY. Bank of America reduced their price objective on shares of Eli Lilly and Company from $1,294.00 to $1,133.00 and set a "buy" rating for the company in a report on Friday, May 1st. Argus increased their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Scotiabank restated an "outperform" rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a report on Tuesday, February 10th. Finally, Leerink Partners lowered their price objective on Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating on the stock in a research note on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $1,220.37.

Eli Lilly and Company Stock Up 2.4%

LLY opened at $1,066.59 on Friday. The firm has a market cap of $1.00 trillion, a price-to-earnings ratio of 37.89, a PEG ratio of 1.16 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm's 50-day simple moving average is $942.87 and its 200-day simple moving average is $1,003.77. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.